Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (raav2)-cftr vector in adult cystic fibrosis patients: A two-part clinical study

Human Gene Therapy

Volumn 14, Issue 11, 2003, Pages 1079-1088

  Flotte, Terence R ^a,b   Sullivan, Kevin ^a   Wetzel, Randall ^b,f   Taylor, George ^b   Carter, Barrie J ^c   Guggino, William B ^b   Zeitlin, Pamela L ^b   Reynolds, Thomas C ^b,e   Heald, Alison E ^c   Pedersen, Patty ^c   Beck, Suzanne ^b,d   Conrad, Carol K ^b,e   Brass Ernst, Lois ^b   Humphries, Margaret ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Targeted Genetics Corporation   (United States)

^d ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DEOXYRIBONUCLEASE; NEUTRALIZING ANTIBODY; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADENO ASSOCIATED VIRUS; ADOLESCENT; ADULT; ARTICLE; BRONCHOSCOPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; ENDOBRONCHIAL DRUG ADMINISTRATION; FEMALE; GENE THERAPY; GENE TRANSFER; HEMOPTYSIS; HUMAN; HUMAN CELL; LUNG DISEASE; MALE; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; RECOMBINANT ADENO ASSOCIATED VIRUS 2 VECTOR; VIRUS RECOMBINANT; VIRUS SHEDDING;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BRONCHI; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDOVIRUS; DNA, RECOMBINANT; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HUMANS; INTERLEUKINS; MALE; VIREMIA; VIRUS SHEDDING;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; ADENOVIRIDAE; ORYCTOLAGUS CUNICULUS; PRIMATES;

EID: 0038488551     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403322124792     Document Type: Article

References (24)

1. AFIONE, S.A., CONRAD, C.K., KEARNS, W.G., CHUNDURU, S., ADAMS, R., REYNOLDS, T.C., GUGGINO, W.B., CUTTING, G.R, CARTER, B.J., and FLOTTE, T.R. (1996). In vivo model of adeno-associated virus vector persistence and rescue. J. Virol. 70, 3235-3241.
2. AITKEN, M.L., MOSS, R.B., WALTZ, D.A., DOVEY, M.E., TONELLI, M.R., MCNAMARA, S.C., GIBSON, R.L., RAMSEY, B.W., CARTER, B.J., and REYNOLDS, T.C. (2001). A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 12, 1907-1916.
3. CONRAD, C.K., ALLEN, S.S., AFIONE, S.A., REYNOLDS, T.C., BECK, S.E., FEE-MAKI, M., BARRAZZA-ORTIZ, X., ADAMS, R., ASKIN, F.B., CARTER, B.J., GUGGINO, W.B., and FLOTTE, T.R. (1996). Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther. 3, 658-668.
4. DUAN, D., YUE, Y., YAN, Z., YANG, J., and ENGELHARDT, J.F. (2000). Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Invest. 105, 1573-1587.
5. EGAN, M., FLOTTE, T., AFIONE, S., SOLOW, R., ZEITLIN, P.L., CARTER, B.J., and GUGGINO, W.B. (1992). Defective regulation of outwardly rectifying C1-channels by protein kinase A corrected by insertion of CFTR [see comments]. Nature 358, 581-584.
6. FLOTTE, T.R., and CARTER, B.J. (1998). Adeno-associated virus vectors for gene therapy of cystic fibrosis. Methods Enzymol. 292, 717-732.
7. FLOTTE, T.R., SOLOW, R., OWENS, R.A., AFIONE, S., ZEITLIN, P.L., and CARTER, B.J. (1992). Gene expression from adeno-associated virus vectors in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 7, 349-356.
8. FLOTTE, T.R., AFIONE, S.A., CONRAD, C., MCGRATH, S.A., SOLOW, R., OKA, H., ZEITLIN, P.L., GUGGINO, W.B., and CARTER, B.J. (1993a). Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. U.S.A. 90, 10613-10617.
9. FLOTTE, T.R., AFIONE, S.A., SOLOW, R., DRUMM, M.L., MARKAKIS, D., GUGGINO, W.B., ZEITLIN, P.L., and CARTER, B.J. (1993b). Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J. Biol. Chem. 268, 3781-3790.
10. GOLDMAN, M., SU, Q., and WILSON, J.M. (1996). Gradient of RGD-dependent entry of adenoviral vector in nasal and intrapulmonary epithelia: Implications for gene therapy of cystic fibrosis. Gene Ther. 3, 811-818.
11. HABERMAN, R.P., MCCOWN, T.J., and SAMULSKI, R.J. (2000). Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J. Virol. 74, 8732-8739.
12. HERNANDEZ, Y.J., WANG, J., KEARNS, W.G., LOILER, S., POIRIER, A., and FLOTTE, T.R. (1999). Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model [In Process Citation]. J. Virol. 73, 8549-8558.
13. KNOWLES, M.R., NOONE, P.G., HOHNEKER, K., JOHNSON, L.G., BOUCHER, R.C., EFTHIMIOU, J., CRAWFORD, C., BROWN, R., SCHWARTZBACH, C., and PEARLMAN, R. (1998). A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Hum. Gene Ther. 9, 249-269.
14. KOTIN, R.M., SINISCALCO, M., SAMULSKI, R.J., ZHU, X.D., HUNTER, L., LAUGHLIN, C.A., MCLAUGHLIN, S., MUZYCZKA, N., ROCCHI, M., and BERNS, K.I. (1990). Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 87, 2211-2215.
15. ROONEY, C.P., DENNING, G.M., DAVIS, B.P., FLAHERTY, D.M., CHIORINI, J.A., and ZABNER, J. (2002). Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis. J. Virol. 76, 10437-10443.
16. SAMULSKI, R.J., ZHU, X., XIAO, X., BROOK, J.D., HOUSMAN, D.E., EPSTEIN, N., and HUNTER, L.A. (1991). Targeted integration of adeno-associated virus (AAV) into human chromosome 19 [published erratum appears in EMBO J. 1992;11:1228]. EMBO J. 10, 3941-3950.
17. SNYDER, R.O., MIAO, C.H., PATIJN, G.A., SPRATT, S.K., DANOS, O., NAGY, D., GOWN, A.M., WINTHER, B., MEUSE, L., COHEN, L.K., THOMPSON, A.R., and KAY, M.A. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16, 270-276.
18. SNYDER, R.O., MIAO, C., MEUSE, L., TUBB, J., DONAHUE, B.A., LIN, H.F., STAFFORD, D.W., PATEL, S., THOMPSON, A.R., NICHOLS, T., READ, MS., BELLINGER, D.A., BRINKHOUS, K.M., and KAY, M.A. (1999). Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors [see comments]. Nat. Med. 5, 64-70.
19. VIRELLA-LOWELL, I., POIRIER, A., CHESNUT, K.A., BRANTLY, M., and FLOTTE, T.R. (2000). Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther. 7, 1783-1789.
20. WAGNER, J.A., REYNOLDS, T., MORAN, M.L., MOSS, R.B., WINE, J.J., FLOTTE, T.R., and GARDNER, P. (1998). Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 351, 1702-1703.
21. WAGNER, J.A., MESSNER, A.H., MORAN, M.L., DAIFUKU, R., KOUYAMA, K., DESCH, J.K., MANLY, S., NORBASH, A.M., CONRAD, C.K., FRIBORG, S., REYNOLDS, T., GUGGINO, W.B., MOSS, R.B., CARTER, B.J., WINE, J.J., FLOTTE, T.R., and GARDNER, P. (1999). Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane conductance regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 109, 266-274.
22. WAGNER, J.A., NEPOMUCENO, I.B., MESSNER, A.H., MORAN, M.L., BATSON, E.P., DIMICELI, S., BROWN, B.W., DESCH, J.K., NORBASH, A.M., CONRAD, C.K., GUGGINO, W.B., FLOTTE, T.R., WINE, J.J., CARTER, B.J., REYNOLDS, T.C., MOSS, R.B., and GARDNER, P. (2002). A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 13, 1349-1359.
23. XIAO, X., LI, J., and SAMULSKI, R.J. (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70, 8098-8108.
24. YAN, Z., ZHANG, Y., DUAN, D., and ENGELHARDT, J.F. (2000). From the cover: Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy [see comments]. Proc. Natl. Acad. Sci. U.S.A. 97, 6716-6721.